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Abstract The aim of this work was to translate the 44-item
SWAL-QoL into Dutch (SWAL-QoL-NL) and compare the
validity of this questionnaire against Euroqol in a Dutch
population with dysphagia. SWAL-QoL was translated
according to international guidelines. SWAL-QoL-NL and
Euroqol were completed by 152 patients in seven diagnosis
groups. Internal consistency and correlations were calcu-
lated. Scores for nine subscales (General burden, Food
selection, Eating duration, Fear of eating, Sleep, Fatigue,
Mental health, Social functioning and a symptom score)
ranged between 0.80 and 0.92 (Cronbach’s a). Two sub-
scales (Eating desire and Communication scored 0.67 and
0.60, respectively, and were removed from the question-
naire. The 14-item battery on clinical symptoms showed an
internal consistency of 0.80, allowing the use of a sum score
on group level in clinical research. Correlation of SWAL-
QoL-NL subscales with the Euroqol was negligible to low
(Pearson’s correlations range = 0.09–0.36). The 39-item
SWAL-QoL-NL proved to be a reliable tool to examine the
impact of dysphagia on quality of life in a Dutch population.
Internal consistency allows the use of nine subscales of
SWAL-QoL-NL for comparisons on a group level (0.80 \
a\ 0.92) only. Also a Symptom score can be derived from
the raw data.
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A large amount of clinical research has been aimed at
evaluating the impact of different diseases and health
problems on the quality of life of patients. In the early
1990s over 160 different measures were used to assess
health-related quality of life (HR-QoL) [1].
Eating and drinking are basic necessities of man. Problems
with swallowing (dysphagia) therefore have severe conse-
quences for the quality of life of patients [2]. In 2000 the
SWAL-QoL was developed by McHorney et al. [3, 4] as a
patient-based, dysphagia-specific tool to evaluate the impact
of swallowing problems on the quality of life in patients with
dysphagia. The SWAL-QoL was initially derived from a 185-
item pool and scaled down to a 93-item questionnaire. Later
this 93-item questionnaire was further reduced into two dif-
ferent questionnaires: the 44-item SWAL-QoL, a dysphagia-
specific quality-of-life questionnaire and the 15-item SWAL-
Care, a questionnaire that evaluates dysphagia therapy from a
patient’s perspective [3]. SWAL-QoL consists of 10 quality-
of-life concepts (General burden, Food selection, Eating
duration, Eating desire, Fear of eating, Sleep, Fatigue, Com-
munication, Mental health and Social functioning with a total
of 30 items and a 14-item battery to provide clinical
researchers and practitioners information on symptoms.
Cronbach’s a coefficients [5] were used by the developers
of SWAL-QoL to determine the internal consistency reli-
ability of each of the ten subscales. According to McHorney
et al. [6], coefficients ranged from 0.79 to 0.91, allowing the
SWAL-QoL to be used only for group-level research
according to Bland and Altman [5]. Thus, SWAL-QoL also
allows researchers to derive sum scores for each of the ten
concepts from the raw data provided by the questionnaire.
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Since its first publication in 2000, SWAL-QoL has shown
to be the gold standard in dysphagia research regarding
quality-of-life issues of patients with dysphagia and is fre-
quently used [7–9]. Although SWAL-QoL has been
translated into and used in other languages, to date no
clinimetrical evaluations have been made of these transla-
tions. In this study we therefore translated the SWAL-QoL
into Dutch (SWAL-QoL-NL) and performed a cross-cultural
adaptation and validation of SWAL-QoL in order to provide
a clinimetrically valid tool for assessing the patients’ per-
spectives of dysphagia treatment in the Netherlands. In our
research design we compared SWAL-QoL-NL to Euroqol as
a general quality-of-life assessment tool [10]. Because both
questionnaires are instruments that measure quality of life,
we hypothesized that some correlation between both
instruments would be found. However, because the SWAL-
QoL was derived from a very dysphagia-specific-item pool
[3, 4] compared to general quality-of-life questions, we
hypothesized that this correlation would not be strong.
Respondents and Methods
Translation of SWAL-QoL
The original SWAL-QoL was translated into the Dutch lan-
guage according to the process of translation and back-
translation as described in international guidelines [1]. This
process yielded the initial 44-item Dutch version of SWAL-
QoL, called SWAL-QoL-NL. Next to the 44-item test battery
of SWAL-QoL-NL, general questions on feeding status,
marital status, education levels, and time-needed-to-complete
SWAL-QoL-NL were evaluated to gather information on
social background and the clinical use of SWAL-QoL-NL.
Euroqol
Euroqol is a standardized instrument for use as a measure of
health outcome. Applicable to a wide range of health condi-
tions and treatments, Euroqol provides a simple descriptive
profile and a single index value for health status. Euroqol is
designed for self-completion by respondents and is developed
for use in postal surveys, clinics, and face-to-face interviews
[10]. Since its introduction in 1990, Euroqol is frequently used
to determine health status of patients in a wide variety of
groups and different research projects [11–13].
Euroqol consists of a visual analog scale (also called the
‘‘thermometer’’) from 0 to 100, on which the respondent
marks his general well-being. Further, Euroqol consists of five
short questions regarding five dimensions or constructs
(hence, in literature the name EQ-5D is also used for Euroqol).
These five explored constructs are Mobility, Self-care, Usual
activities, Pain and Discomfort, and Anxiety and Depression.
Respondents
To establish a broad range of respondents, patients diag-
nosed with (oropharyngeal) dysphagia based on a variety of
diagnoses were recruited from the outpatient clinics of two
large university hospitals (Amsterdam and Maastricht).
Also, a range of patients with oropharyngeal dysphagia in
nursing home facilities across the Netherlands were asked
to participate. All possible respondents were asked to
complete both Euroqol and SWAL-QoL-NL.
Statistical Analysis and Considerations
For statistical analysis SPSS 12.0 (SPSS Inc, Chicago, IL,
USA) was used. Internal consistency of the SWAL-QoL-
NL was calculated using Cronbach’s a. Correlations
between the subscales of the SWAL-QoL-NL and the EQ-
5D were determined by calculating the Pearson’s correla-
tion coefficient (r). According to Bland and Altman [5],
Cronbach’s a values between 0.7 and 0.8 were regarded as
satisfactory for comparing on group level, and values of 0.9
and higher were considered to be needed for individual
applications. For the correlation coefficients (r), a mini-
mum value for a strong correlation was set at 0.7 and above
[14–16]. Correlation coefficients between 0.3 and 0.7 were
considered to be a substantial correlation only, and r\0.3
was considered to be a weak correlation.
For additional analysis, all data were formally tested for
normality with the Kolmogorov-Smirnoff test for normal-
ity. Based on normality, unpaired tests were used to
explore differences in (sum) scores between different
patient groups.
Results
SWAL-QoL-NL and Euroqol were completed by 152
respondents, who ranged in age from 19.7 to 91.2 years old
(mean = 64.8 ± 13.2) and 65% were male. Respondents
could be split into seven different diagnostic groups (stroke
28%, Parkinson 24%, neuromuscular diseases 9%, other
neurologic diseases 16%, head and neck oncology 11%,
idiopathic cricopharyngeal problems 5%, and unknown
etiology 7%). A vast majority of patients (133 of 152) were
on an oral diet, 12.5% (n = 19) was dependent on tube
feeding. Of all respondents, 69.7% had at least a second-
ary-level education (high school) or higher. Over 60% were
married or living with a partner. Respondents’ character-
istics are presented in Table 1.
Over 60% of all respondents received help to complete
the questionnaires. This help mainly consisted of another
person reading the questions and writing down the answers
(83%). In only 7 cases (7%) somebody else answered the
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questions for the respondent. For respondents who received
help it took 22 minutes (range = 1–60) to complete
SWAL-QoL-NL; respondents who completed the ques-
tionnaire by themselves took fractionally less time: 20 min
on average (range = 1–60). Table 2 shows the clinical use
of SWAL-QoL-NL.
For each of the ten subscales, the sum scores were
derived from the questionnaires. Mean scores on the sub-
scales ranged from 42.9 to 82.9, where a score of ‘‘0’’
represents the worst possible score and ‘‘100’’ the most
optimal score. Cronbach’s a coefficients on the SWAL-
QoL-NL ranged from 0.60 to 0.92 on the ten subscales. In
addition, a sum score and Cronbach’s a were calculated for
the 14-item symptom battery and was estimated to be 62.4
(±18.3) and 0.80, respectively. Table 3 shows the clini-
metrical characteristics of the SWAL-QoL-NL.
Mean score on the EQ-5D visual analog scale (VAS)
was 59.9 (±19.5). On the Euroqol subscale Mobility, 62%
of our patients reported a problem. Percentages of patients
reporting any problems on the subscales Self-care, Usual
activities, Pain/Discomfort and Anxiety/Depression were
53, 61, 45, and 30, respectively. The subscales Mobility
and Self-care revealed statistically different scores com-
pared with the other subscales of Euroqol (Kruskal-Wallis;
p \ 0.001). Table 4 shows the scores on Euroqol for our
patient group.
Clinical validity of SWAL-QoL-NL was assessed by
correlating the subscale scores on SWAL-QoL-NL with the
five subscales and the VAS scores on Euroqol. Pearson’s
correlation coefficients ranged from -0.24 to 0.36, show-
ing in general a weak correlation between the two
assessment tools. Significant (2-tailed) correlations at a
0.01 level were found between the Euroqol VAS score and
three SWAL-QoL-NL subscales (Eating duration, Fatigue
and Social effects. At a 0.05 level three further significant
correlations were found. The correlations between the
subscores on the SWAL-QoL-NL and the Euroqol are
shown in Table 5.
Table 1 Patients’ characteristics (n = 152)
Characteristic Number
Gender
Male 99 (65%)
Female 52 (34%)
Missing 1 (1%)
Age 64.8 ± 13.2 (19.7–91.2)a
Diagnosis
Stroke 43 (28.3%)
Parkinson’s disease 36 (23.7%)
Neuromuscular diseases 13 (8.6%)
Other neurologic diseases 25 (16.4%)
Head and neck oncology 17 (11.2%)
Cricopharyngeal problems 8 (5.3%)
Unknown 10 (6.6%)
Education
Primary 41 (27.0%)
Secondary 74 (48.6%)
University 32 (21.1%)
Missing 5 (3.3%)
Marital status
Single 24 (15.8%)
Married/cohabiting 95 (62.5)%
Separated 9 (5.9%)
Widowed 22 (14.5%)
Missing 2 (1.4%)
Tube feeding 19 (12.5%)
Euroqol VAS score 59.9 ± 19.5 (0–99)a
a Mean ± SD (minimum–maximum)
Table 2 Clinical use of SWAL-QoL-NL
Was patient helped with questionnaire? When helped, how? n Time (min)
No 58 (38.2%) 19.6 ± 8.9 (1–60)
Yes 94 (61.8%) 21.5 ± 8.8 (1–60)
Read questions/wrote down answers 83 (83.3%)
Caregiver answered for the patient 7 (7.4%)
Other 4 (4.3%)
Table 3 Reliability coefficients of Dutch version of SWAL-QoL
Subscale n No. items Mean SD Cronbach’s a
General burden 152 2 47.3 31.6 0.84
Food selection 144 2 62.3 29.2 0.87
Eating duration 147 2 42.9 32.6 0.82
Eating desire 149 3 69.6 28.2 0.67
Fear of eating 149 4 82.9 21.1 0.83
Sleep 150 2 67.3 32.0 0.80
Fatigue 149 3 60.8 27.4 0.83
Communication 152 2 56.8 28.3 0.60
Mental health 152 5 66.8 26.9 0.89
Social functioning 149 5 58.0 31.1 0.92
Symptoms 137 14 62.4 18.3 0.80
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Discussion
In our study we made a cross-cultural adaptation of SWAL-
QoL and validated this assessment tool against Euroqol in
152 Dutch patients with dysphagia. None of the subscales of
SWAL-QoL-NL reached an internal consistency of 0.95 or
higher. Nine subscale scores (General burden, Food selec-
tion, Eating duration, Fear of eating, Sleep, Fatigue, Mental
health, Social functioning and a symptom score) ranged
between 0.80 and 0.92 (Cronbach’s a) and can be used for
assessment of quality of life in dysphagic patients on a
group level. Two subscales (Eating desire and Communi-
cation scored only 0.67 and 0.60, respectively, and are less
suitable for clinical research. In the final version of SWAL-
QoL-NL these two subscales with three and two items,
respectively, were removed, reducing the questionnaire to a
39-item tool.
In literature it is described that there are differences in
health-related quality of life measures between different
cultures. In 1988 Flaherty et al. [17] already described that
researchers should give particular attention to cross-cul-
tural validity when an instrument designed in one culture is
used in a second culture. Consequently, in 1993 Guillemin
et al. [1] described their guidelines for cross-cultural
adaptation of health-related quality-of-life measures based
on a systematic review of translated questionnaires. Our
study shows that some cultural differences seem to exist
between dysphagia patients in the U.S. and in the Nether-
lands. This supports the findings of Guillemin et al. [1] that
one should thoroughly investigate a translated question-
naire clinimetrically before using it in another language.
Although the subscales Eating desire and Communication
are valid in the original version of SWAL-QoL, they are
not psychometrically valid for use in the Netherlands.
Researchers in the Netherlands should be aware of these
findings when comparing their SWAL-QoL-NL outcomes
with the outcomes measured by the original SWAL-QoL in
other publications. Also, Dutch researchers should specif-
ically address in their reports that they have used SWAL-
QoL-NL in their research and not the original 44-item
version.
Interestingly, the 14-item battery that provides clinical
researchers and practitioners information on symptoms had
an internal consistency of 0.80, allowing the use of a sum
score for these 14 items on a group level. We renamed this
14-item battery the Symptom score. This symptom score
Table 4 Percentage of
respondents with any problem
on Euroqol
a Kruskal-Wallis
b No significant differences
between groups
Diagnosis n Mobility Self-care Usual
activities
Pain/
discomfort
Anxiety/
depression
All patients 115 61.8 52.6 61.2 44.7 29.6
Stroke 42 88.1 83.3 85.7 50.0 47.6
Parkinson’s disease 6 83.3 83.3 83.3 50.0 50.0
Neuromuscular diseases 12 100.0 76.9 84.6 53.8 30.8
Other neurologic diseases 25 92.0 76.0 68.0 56.0 32.0
Head and neck oncology 14 50.0 30.8 92.9 71.4 35.7
Esophageal problems 7 57.1 28.6 28.6 100.0 28.6
Unknown 9 66.7 55.6 88.9 66.7 33.3
p value 0.003a 0.000a 0.194a,b 0.056a,b 0.128a,b
Table 5 Clinical validity:
correlation of Dutch SWAL-
QoL with Euroqol
a Significant at 0.01 level
(2-tailed)
b Significant at 0.05 level
(2-tailed)
Subscale VAS score Mobility Self-care Usual
activities
Pain/
discomfort
Anxiety/
depression
General burden 0.13 0.16 -0.02 -0.07 0.04 -0.11
Food selection 0.08 0.10 -0.03 -0.03 0.05 -0.06
Eating duration 0.29a 0.00 -0.02 -0.17 -0.18 -0.05
Eating desire 0.12 -0.03 -0.11 -0.16 0.07 -0.11
Fear of eating 0.09 0.09 0.10 0.10 0.01 -0.13
Sleep 0.06 -0.01 0.04 -0.68 -0.03 -0.18
Fatigue 0.36a -0.06 0.03 -0.16 -0.19b -0.24b
Communication 0.04 -0.02 -0.17 -0.09 0.05 -0.10
Mental health 0.17 0.16 0.08 -0.07 0.01 -0.17
Social effects 0.27a 0.03 -0.10 -0.16 0.05 -0.24b
Symptoms 0.14 0.13 0.10 -0.10 -0.10 -0.17
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can be derived from the raw data in the same way as the
other subscale scores are calculated. Although the symp-
tom score can be used only on a group level, it allows
researchers to represent a variety of clinical symptoms in
one severity score ranging from 0 (worst situation) to 100
(no problems).
The weak correlation in general between SWAL-QoL-NL
and Euroqol shows that both instruments are measuring two
related but different constructs. The correlations between
three SWAL-QoL-NL subscales (Eating duration, Social
effects and Fatigue and the VAS score on Euroqol were
found to be significantly correlated. The correlations for the
first two constructs were found to be weak, but the correlation
between the SWAL-QoL-NL subscale Fatigue and the VAS
score on Euroqol (r = 0.36) can be marked as substantial
(r C 0.30) and satisfactory for group-level comparisons
[15]. These findings support the hypothesis that there is a
small overlap between the two quality-of-life questionnaires
but that SWAL-QoL measures a very specific construct
compared to more general quality-of-life issues. The three
described correlations were significant at a 0.01 level. There
were also three other significant correlations found, but only
at a 0.05 level. These weak correlations might support the
findings described above, but considering the fact that 66
correlations were calculated for Table 5, these significant
findings might also be interpreted as a type 1 error.
Combined with the high internal consistency scores
(0.80 and above), SWAL-QoL-NL can be considered a
reliable tool to assess the effects of dysphagia on quality of
life in different patient populations.
Conclusion
SWAL-QoL-NL proved to be a reliable tool to measure
quality of life in patients with oropharyngeal dysphagia.
Nine subscales can be used for assessment of quality of life
in dysphagic patients on a group level. Two subscales (with
a total of 5 items) could be removed from the item list,
reducing the SWAL-QoL-NL to a 39-item tool. Interest-
ingly, in the Dutch version a sum score can be derived from
the items about clinical symptoms, allowing the use of a
single score representing the severity of clinical symptoms.
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